To make administration of an effective drug treatment easier for patients with hand tremors or swallowing difficulties, Adare Pharma Solutions developed a convenient sprinkle formulation. 

THE CHALLENGE 
Patients who experience tremors and other persistent uncontrolled body movements caused by certain neurological conditions face significant challenges affecting their quality of life and peace of mind. Our customer, a mid-size pharmaceutical company, markets a drug treatment product that can help alleviate these symptoms. 

However, many of these patients have coexisting conditions that make administration of the medication’s capsule form difficult and could lead to poor adherence. An estimated 5% to 10% of patients with these neurological conditions struggle with dysphagia, making it difficult or impossible to swallow traditional capsules. Additionally, patients with severe tremors and uncontrolled hand movements encounter physical challenges when handling and swallowing capsules.  

Recognizing the need for a more accessible alternative form of its product, the company reached out to the scientists at Adare to develop an alternative administration option. 

THE SOLUTION 
Adare’s team of patient-centric formulation experts used our MMTS Minitabs technology to develop a sprinkle form of the drug product that directly addressed these challenges. 

This new form consists of oral granules that can be easily sprinkled over soft food or mixed into a liquid, providing a flexible and convenient administration method. By eliminating the need to swallow capsules, the sprinkle form provides a much-needed solution for patients with swallowing difficulties or hand tremors. 

To make the sprinkle a reality, though, our team had to drive innovation in the manufacturing process. We developed a novel method that increases the compression folds of the minitablets to ensure they withstand the hardening process of the sprinkle’s taste-masking coating and remain intact throughout production. This not only solved a challenge for this specific project but also provided a valuable technique for future microencapsulation projects, setting the stage for further innovation. 

THE RESULT 
The sprinkle form of our customer’s drug was approved by the FDA in Spring 2024 and is now shipping to patients in North America. Clinical trials are underway to expand its availability to other regions, ensuring that even more patients will soon benefit from this product. 

Patients with dysphagia can now take our customer’s important medication without fear of discomfort or choking, helping contribute to consistent and safe administration. For patients with severe tremors, the sprinkle form simplifies the process of taking their medication, reducing frustration and improving adherence. Caregivers also benefit from the easier administration process, resulting in less stress and better overall patient care.  

This solution not only enhances patient quality of life but also underscores Adare’s commitment to patient-centric care. By helping our customers prioritize the real-world needs of their patients, Adare continues to be a leader in developing practical, effective treatments that enhance the well-being of all patients.